Cancer Biology

861 Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

860 Naked mole rats can undergo developmental, oncogene-induced and DNA damage-induced cellular senescence.

859 Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.

858 Renal cell cancers with mutations in a specific chromatin regulator have a better clinical response to immunotherapy.

857 Inactivation of a chromatin remodeling complex in tumor cells enhances their sensitivity to killing by T cells.

856 Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury.

855 Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.

854 A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.

853 Targeting IRF3 as a YAP agonist therapy against gastric cancer.

852 Asparagine bioavailability governs metastasis in a model of breast cancer.

851 Targeting of p53- and PUMA-dependent apoptosis protects intestinal stem cells, but not cancer cells, against chemotherapy.

850 HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

849 Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria.

848 Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

847 Eradication of spontaneous malignancy by local immunotherapy.

846 Elevated d-2-hydroxyglutarate during colitis drives progression to colorectal cancer.

845 Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells.

844 Detection and localization of surgically resectable cancers with a multi-analyte blood test.

843 Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus.

842 Rapid drug screen using 3D tumor organoids.

Free Images for Presentation: sunipix SUNIPIX